Scott+Scott is counsel in a consolidated class action pending in the Southern District of New York, In re: Chantix (Varenicline) Marketing, Sales Practices and Products Liability Litigation (No. II), 22-md-3050 (KPF), 22-mc-3050 (KPF) (S.D.N.Y.), on behalf of consumers and third-party payers that purchased varenicline-containing medications under the brand name Chantix® (“Chantix”) manufactured and sold by Defendant Pfizer, Inc. (“Pfizer”).

Plaintiffs allege that Chantix was contaminated with dangerously high levels of N-nitroso-varenicline, a carcinogenic substance. Pfizer’s drugs also were not manufactured in compliance with current Good Manufacturing Practices (cGMPs). Because nitrosamines are not active or inactive components of Chantix, plaintiffs allege that the presence of nitrosamine contaminants in a drug such as Chantix, as well as Pfizer’s significant cGMP violations, each rendered its product adulterated and misbranded under federal and analogous state laws, and therefore economically worthless and illegal to sell. Plaintiffs bring claims for breach of express and implied warranty, fraud, negligent misrepresentation and omission, violation of state consumer protection laws, violation of the Magnuson-Moss Warranty Act, negligence, negligence per se, and unjust enrichment.